Jinyao Pharmaceutical Co Ltd

Jinyao Pharmaceutical maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.22, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.49, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. Free cash flow stands at 303,945,540 CNY, which is a positive sign for operational flexibility and reinvestment potential. Profitability metrics show a return on equity (ROE) of 4.36% and a return on assets (ROA) of 2.34%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These figures suggest that the company is generating modest returns relative to its equity and asset base. Gross profit of 1,423,564,510 CNY represents 44.27% of total revenue, which is in line with industry norms, but the operating margin of 7.02% is relatively low, indicating potential inefficiencies in cost management or pricing power. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification beyond the domestic Chinese market. This lack of diversification increases exposure to local economic and regulatory risks, which could impact revenue stability. Looking ahead, the company's revenue is expected to grow, with the current fiscal year showing a revenue of 3,215,285,230 CNY and a trailing twelve-month revenue of 2,427,864,590 CNY. However, the growth trajectory is not yet quantified in the next fiscal year, and the capital expenditure of -77,740,240 CNY suggests a reduction in investment in new projects or facilities. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to fund operations or pursue growth opportunities without external financing. No significant dilution sources are identified in the current period, and the dilution risk is assessed as low. Recent events include the latest financial filing, which provides the most recent revenue and profitability figures. No recent earnings call transcripts or major regulatory filings have been disclosed in the available data.